Research Roundup

OFFICIAL PUBLICATION OF

by its subsidiary APPco

Debbie Rigby 03/09/2019

Debbie Rigby rounds up the latest in research news Reduction in Use of Risperidone for Dementia in Australia Risperidone is the only antipsychotic approved in Australia for the management of the behavioural and psychological symptoms of dementia (BPSD). In June 2015, the TGA amended the indication to restrict use in BPSD to patients with Alzheimer’s

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

ACCC announces Chemist Warehouse/Sigma merger decision

I didn't realise there was a reply deadline here? Feel free to take your time and respond when you can…

John Smith

Counterfeit ivermectin

I disagree with you Leo, the TGA is our national regulator of medicines and medical devices and they do have…

Brad Sparling

Sigma/CWH merger to change pharmacy

Yeh their entire business model is to put Priceline in their shopping centres paying 3-4x the amount of rent a…

Bob Tran

Sigma/CWH merger to change pharmacy

The problem Wesfarmers have is that their control over individual Pricelines is too small compared to CWH. Any greater control…

Paul Sapardanis

Research Roundup

Previous GPs, practice staff value community pharmacy ‘safety net’

Next We're back

In the beginning

The signs of ageing

Hyperpigmentation

How to avoid dry skin

MENU

Previous GPs, practice staff value community pharmacy ‘safety net’

Next We're back

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.